Kyverna Therapeutics (KYTX) Assets Average (2024 - 2026)

Kyverna Therapeutics' Assets Average history runs 3 years deep, the most recent figure standing at $275.4 million for Q1 2026.

• Quarterly Assets Average fell 2.56% year-over-year to $275.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.4 million (down 2.56% YoY) and the FY2025 annual result came in at $299.2 million, up 57.56% from the prior year.
• Assets Average was $275.4 million for Q1 2026 at Kyverna Therapeutics, up from $240.5 million in the prior quarter.
• Across five years, Assets Average topped out at $376.6 million in Q2 2024 and bottomed at $206.8 million in Q3 2025.
• A 3-year average of $281.2 million and a median of $275.4 million in 2026 frame the typical range for Assets Average.
• Peak annual rise in Assets Average reached 21.52% in 2025, while the deepest fall reached 41.1% in 2025.
• Kyverna Therapeutics' Assets Average stood at $321.9 million in 2024, then fell by 25.29% to $240.5 million in 2025, then grew by 14.53% to $275.4 million in 2026.
• Business Quant data shows KYTX's Assets Average at $275.4 million in Q1 2026, $240.5 million in Q4 2025, and $206.8 million in Q3 2025.